Iniciar Sesión Regístrate abrir menu

Bibliografía Científica

Artículos por temáticas

En este apartado encontrará una actualización mensual de Enfermedad de Alzheimer y Demencias

134 ARTÍCULOS , VIENDO DEL 106 AL 120

Overview and recent advances in neuropathology. Part 2: Neurodegeneration

Masters CL, Kril JJ, Halliday GM, Pamphlett R, Collins S, Hill AF, McLean C.

Pathology. 2011 Feb;43(2):93-102. doi: 10.1097/PAT.0b013e3283426eee.

Operationalizing diagnostic criteria for Alzheimer's disease and other age-related cognitive impairment-Part 1

Mayeux R, Reitz C, Brickman AM, Haan MN, Manly JJ, Glymour MM, Weiss CC, Yaffe K, Middleton L, Hendrie HC, Warren LH, Hayden KM, Welsh-Bohmer KA, Breitner JC, Morris JC.

Alzheimers Dement. 2011 Jan;7(1):15-34. doi: 10.1016/j.jalz.2010.11.005.

Pre-dementia clinical stages in presenilin 1 E280A familial early-onset Alzheimer's disease: a retrospective cohort study

Acosta-Baena N, Sepulveda-Falla D, Lopera-Gómez CM, Jaramillo-Elorza MC, Moreno S, Aguirre-Acevedo DC, Saldarriaga A, Lopera F.

Lancet Neurol. 2011 Mar;10(3):213-20. doi: 10.1016/S1474-4422(10)70323-9. Epub 2011 Feb 4.

Epidemiology of Alzheimer disease

Reitz C, Brayne C, Mayeux R.

Nat Rev Neurol. 2011 Mar;7(3):137-52. doi: 10.1038/nrneurol.2011.2. Epub 2011 Feb 8.

Qualification of the analytical and clinical performance of CSF biomarker analyses in ADNI

Shaw LM, Vanderstichele H, Knapik-Czajka M, Figurski M, Coart E, Blennow K, Soares H, Simon AJ, Lewczuk P, Dean RA, Siemers E, Potter W, Lee VM, Trojanowski JQ; Alzheimer's Disease Neuroimaging Initiative.

Acta Neuropathol. 2011 May;121(5):597-609. doi: 10.1007/s00401-011-0808-0. Epub 2011 Feb 11.

Lysosomal β-galactosidase and β-hexosaminidase activities correlate with clinical stages of dementia associated with Alzheimer's disease and type 2 diabetes mellitus

Tiribuzi R, Orlacchio A, Crispoltoni L, Maiotti M, Zampolini M, De Angeliz M, Mecocci P, Cecchetti R, Bernardi G, Datti A, Martino S, Orlacchio A.

J Alzheimers Dis. 2011;24(4):785-97. doi: 10.3233/JAD-2011-100525.

Alzheimer's disease

Ballard C, Gauthier S, Corbett A, Brayne C, Aarsland D, Jones E.

Lancet. 2011 Mar 19;377(9770):1019-31. doi: 10.1016/S0140-6736(10)61349-9. Epub 2011 Mar 1.

The MTHFD1L gene rs11754661 marker is not associated with Alzheimer's disease in a sample of the Spanish population

Ramírez-Lorca R, Boada M, Antúnez C, López-Arrieta J, Moreno-Rey C, Hernández I, Marín J, Gayán J, González-Pérez A, Alegret M, Tárraga L, Real LM, Ruiz A.

J Alzheimers Dis. 2011;25(1):47-50. doi: 10.3233/JAD-2011-101983.

Gene expression profiling of peripheral blood leukocytes identifies and validates ABCB1 as a novel biomarker for Alzheimer's disease

Chen KD, Chang PT, Ping YH, Lee HC, Yeh CW, Wang PN.

Neurobiol Dis. 2011 Sep;43(3):698-705. doi: 10.1016/j.nbd.2011.05.023. Epub 2011 Jun 6.

Is hyperhomocysteinemia an Alzheimer's disease (AD) risk factor, an AD marker, or neither?

Zhuo JM, Wang H, Praticò D.

Trends Pharmacol Sci. 2011 Sep;32(9):562-71. doi: 10.1016/j.tips.2011.05.003. Epub 2011 Jun 20.

The MTHFD1L gene rs11754661 marker is associated with susceptibility to Alzheimer's disease in the Chinese Han population

Ren RJ, Wang LL, Fang R, Liu LH, Wang Y, Tang HD, Deng YL, Xu W, Wang G, Chen SD.

J Neurol Sci. 2011 Sep 15;308(1-2):32-4. doi: 10.1016/j.jns.2011.06.036. Epub 2011 Jul 8.

Alzheimer's disease

Brody H.

Nature. 2011 Jul 13;475(7355):S1. doi: 10.1038/475S1a.

The role of reelin gene polymorphisms in the pathogenesis of Alzheimer's disease in a Greek population

Antoniades D, Katopodi T, Pappa S, Lampropoulos A, Konsta V, Frydas E, Mpalogiannis S, Hatzistilianou M.

J Biol Regul Homeost Agents. 2011 Jul-Sep;25(3):351-8.

C-peptide and its correlation to parameters of insulin resistance in the metabolic syndrome

Banu S, Jabir NR, Manjunath CN, Shakil S, Kamal MA.

CNS Neurol Disord Drug Targets. 2011 Dec;10(8):921-7. doi: 10.2174/187152711799219271.

Actualización mensual Regístrese para recibir los avisos de actualización

Si quiere recomendar un artículo/publicación para completar este apartado puede hacerlo a través del formulario de contacto para su valoración.

En ningún caso la información facilitada constituye asesoramiento por parte de Zambon

Con el aval de:

Logo SEN Logo WIS

En colaboración con:

Zambon Neurociencias